Trial Profile
A Phase I, Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblind), Three Part Study to Evaluate the Safety, Tolerability, Preliminary PK and PD of Single and Repeat Oral Doses of GSK3008356 in Healthy Subjects and Obese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs BOS 356 (Primary)
- Indications Acne
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
- 12 Jul 2017 Status changed from recruiting to completed.
- 18 May 2017 Planned End Date changed from 1 May 2017 to 1 Jun 2017.
- 18 May 2017 Planned primary completion date changed from 1 May 2017 to 1 Jun 2017.